Prostatic Hyperplasia
Conditions
Keywords
Benign Prostatic Hyperplasia, dutasteride and tamsulosin
Brief summary
Open-label, 6 month-treatment with the IP in all subjects. - Sample size: A total of 90 subjects will be enrolled so that among them at least 57 will complete the 6-month treatment period and evaluable for analysis. -Primary objective: To assess the safety of 0.5 mg dutasteride/0.4 mg tamsulosin combination therapy for six month in BPH patients by monitoring category, frequency and severity of adverse events encountered during the treatment period. -Secondary objective: To assess the efficacy of 0.5 mg dutasteride/0.4 mg tamsulosin combination therapy with regard to symptom improvement in BPH patients by monitoring and analyzing of changes in IPSS and Qmax after 6 months of treatment.
Detailed description
Visit 0 or Screening Visit (M0) - D0 + 2): Following tasks will be performed: ICF collection, subject code assignment, physical examination (vital signs, demographic data, medical history); checking of inclusion and exclusion criteria: prostate symptom score according to IPSS, laboratory tests (hematology, blood chemistry, electrolytes, total PSA level, free-to-total PSA ratio, Qmax, urinalysis, transrectal prostate ultrasonography (TRUS), 12-lead electrocardiography (ECG), scoring of Sexual Function Questionnaire (SFQ), concomitant medication assessment, IP dispensing. • Visit 1 (Month 1 (M1) - D30 ± 3): Following items will be recorded: treatment compliance, vital signs, blood chemistry, ECG, adverse events (AEs), concomitant medication; dispensing of new IP doses and collecting of dispensed IP at the last visit. • Visit 2 (Month 2 (M2) - D60 ± 3): Following items will be recorded: treatment compliance, AEs, concomitant medication; dispensing of new IP doses and collecting of dispensed IP at the last visit. • Visit 3 (Month 3 (M3) - D90 ± 3): Following items will be recorded: vital signs, laboratory tests (hematology, blood chemistry, electrolytes, Qmax, urinalysis, 12-lead ECG, total PSA level), concomitant medication, SFQ score, AE assessment, collecting of dispensed IP at the last visit and dispensing of new IP doses. • Visit 4 (Month 4.5 (M4) - D135 ± 3): Following items will be recorded: treatment compliance, vital signs, AEs, concomitant medication; dispensing of new IP doses and collecting of dispensed IP at the last visit. Visit 5 (Month 6 (M6)- D180 ± 3): Following items will be recorded: treatment compliance, vital signs, prostate symptom score according to IPSS, laboratory tests (hematology, blood chemistry, electrolytes, Qmax, urinalysis, 12-lead ECG, total PSA level, free-to-total PSA ratio, TRUS; concomitant medication, SFQ score, AE assessment, collecting of the previous dispensed IPs . Follow-up Phone Call (Month 7 (M7)- D210 ± 3): To record any possible AE that may occur after discontinuation of study treatment.
Interventions
0.5 mg dutasteride/ 0.4 mg tamsulosin once daily for the duration of 180 day -treatment
Sponsors
GlaxoSmithKline
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
50 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Male, age ≥ 50 years. Clinical diagnosis of benign prostate hypertrophy (BPH) . International Prostate Symptom Score (IPSS) ≥ 12 Prostate volume ≥30 ml (transrectal ultrasonography). Total serum prostate specific antigen (PSA) ≥1.5 ng/mL and ≤10 ng/mL. Free-to-total PSA ratio \> 20% Maximum flow rate (Qmax) \>5 mL/sec and ≤15 mL/sec and post-void residual volume of \< 150 mL Willing and able to give written informed consent and comply with study procedures throughout study Able to swallow and retain oral medication Able to express personal thought and feeling Ability to read and comprehend information on the Sexual Function Inventory
Exclusion criteria
History or evidence of prostate cancer (e.g. positive biopsy or ultrasound, suspicious digital rectal examination). Previous prostatic surgery (TURP, balloon dilatation, thermotherapy and stent replacement) or other invasive procedures to treat BPH. History of flexible/rigid cystoscopy or other instrumentation of the urethra within past 7 days History of acute urine retention (AUR) within past 3 months. Any causes other than BPH result in urinary symptoms or changes in flow rate (e.g. neurogenic bladder, bladder neck contracture, urethral stricture, bladder malignancy, acute or chronic prostatitis, acute or chronic urinary tract infections). History of breast cancer or clinical finding suggestive of malignancy. Use of any 5-alpha-reductase inhibitor (e.g. Proscar®, Propecia®), drugs with antiandrogenic properties (e.g. spironolactone, flutamide, bicalutamide, cimetidine, ketoconazole, progestational agents), drugs which induce gynecomastia or drugs which affect prostate volume, within past 6 months and throughout the study (other than as study medication). Do not use dutasteride within past 12 months. Do not use metronidazole for a long time. Concurrent use of anabolic steroids (eg. Durabolin®). Use of phytotherapy (eg: Tadenan®, Permixon®, etc) for BPH within 2 weeks of screening visit and/or predicted to need phytotherapy during the study. Use of any alpha-adrenoreceptor blockers (i.e. indoramin, prazosin, terazosin, tamsulosin, alfuzosin and doxazosin) within 2 weeks of screening visit and/or predicted to need any alpha blockers other than tamsulosin during the study. Use of any alpha-adrenoreceptor agonists (e.g. pseudoephedrine, phenylephrine, ephedrine) or anticholinergics (e.g. oxybutynin, propantheline) or cholinergics (e.g. bethanecol chloride) within 48 hours prior to all uroflowmetry assessments. Hypersensitivity to any alpha-/beta-adrenoreceptor blocker or 5-alpha-reductase inhibitor, or other chemically-related drugs. Concurrent use of drugs known or thought to have an interaction with tamsulosin and dutasteride. History of hepatic impairment or abnormal liver function tests at screening (defined ALT, AST, and/or alkaline phosphatase \>2 times the upper limit of normal, or total bilirubin \>1.5 times the upper limit of normal). History of renal insufficiency, or serum creatinine \>1.5 times the upper limit of normal at screening. History of malignancies other than basal cell carcinoma or squamous cell carcinoma of the skin within the past 5 years. Subjects with a prior malignancy who have had no evidence of disease for at least 5 years prior to screening are eligible. Any unstable, serious co-existing medical condition(s) including, but not limited to, myocardial infarction, coronary bypass surgery, unstable angina, cardiac arrhythmias, clinically evident congestive heart failure, or cerebrovascular accident within past 6 months; medically uncontrollable diabetes or peptic ulcer disease History of postural hypotension, dizziness, vertigo or any signs and symptoms of orthostasis, which in judgments of investigator, could be exacerbated by tamsulosin History of unsuccessful treatment with tamsulosin or 'first dose' hypotensive episode on initiation of alpha-1-adrenoreceptor antagonist therapy. History of unsuccessful treatment with finasteride or dutasteride. Willing to have a child during the treatment period or within 6 months thereafter Having female partner who is a pregnant woman or in child-bearing age and refuse to use condom for sexual protection Willing to donate blood during treatment period or within 6 months thereafter. History or current evidence of drug or alcohol abuse within past 12 months. History of any illness might confound the results of the study or poses additional risk to the patient. Participation in investigational or marketed drug trial within 30 days preceding the screening visit and/or during the study treatment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Free to Total PSA Ratio at the Indicated Time Points | Baseline, Month 6 | Serum sample was collected at Screening (Baseline for participants with Free to Total PSA ratio at Month 6), and Month 6 for assessment of free to total PSA ratio. PSA is a substance produced by prostate gland, and the elevated level of PSA indicates prostate cancer or any other non-cancerous condition related to prostate. Free to total PSA ratio at Baseline for participants with free to total PSA Ratio at Month 6 and free to total PSA ratio at month 6 are presented. |
| Number Participants With a Negative or Positive Response at the Indicated Time Points | Screening, Month 3 and Month 6 | Urine samples were collected at Screening (SC), Month 3 (3M) and Month 6 (6M) for urinalysis laboratory assesment. Final value (FV) is defined as the latest post-Baseline value available in the study for each parameter.Urinalysis parameters included erythrocytes, glucose, ketones, leukocytes and protein. Number of participants with a negative (NEG) or positive (POS) response at the indicated time points are summarized. |
| Change From Baseline in Total Prostate -Specific Antigen (PSA) at the Indicated Time Points | Baseline, Month 3 and Month 6 | Serum sample was collected at Baseline, Month 3 and Month 6 for assesment of total PSA. PSA is a substance produced by prostate gland, and the elevated level of PSA indicates prostate cancer or any other non-cancerous condition related to prostate. Change from Baseline in total PSA at Month 3 and Month 6 was calculated as value at specified visist minus Baseline value. |
| Number of Participants With Any On-treatment Adverse Events (AEs) or Any Serious Adverse Event (SAEs) and Treatment-related AEs | From start of study medication until follow-up (up to 7 months) | An AE is defined as any untoward medical occurrence in a participant temporally associated with the use of a medicinal product at any dose, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, is an important medical event that jeopardizes the participants or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition, and is associated with liver injury and impaired liver function. |
| Number of Participants With Any Post-treatment Adverse Events (AEs) or Any Serious Adverse Event (SAEs) and Treatment-related AEs | From start of study medication until follow-up (up to 7 months) | An AE is defined as any untoward medical occurrence in a participant temporally associated with the use of a medicinal product at any dose, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, is an important medical event that jeopardizes the participants or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition, and is associated with liver injury and impaired liver function. |
| Number of Participants With Abnormal Electrocardiogram (ECG) Findings at the Indicated Time Points | Screening, Month 1, Month 3 and Month 6 | A 12 lead ECG was measured at Screening, Month 1 (Visit 1), Month 3 (Visit 3) and Month 6 (Visit 5). |
| Number of Participants With Clinical Chemistry Values Shift From Normal at Baseline to Abnormal at Any Time Post-Baseline | Screening, Month 1, Month 3 and Month 6 | Blood samples were collected at Screening, Month 1 (Visit 1), Month 3 (Visit 3) and Month 6 (Visit 5) for chemistry laboratory assessments. Clinical chemistry parameters included alanine aminotrasferase (ALT), aspartate aminotrasferase (AST), creatinine, glucose, potassium, protein, sodium and urea. The number of participants with a shift from normal at Baseline to abnormal at any time post-Baseline for a clinical chemistry parameter are summarized. |
| Number of Participants With Hematology Values Shift From Normal at Baseline to Abnormal at Any Time Post-Baseline | Screening, Month 3 and Month 6 | Blood samples were collected at Screening, Month 3 (Visit 3) and Month 6 (Visit 5) for hematology laboratory assessments. Hematology parameters included basophils, leukocytes, hemoglobin (HGB), eosinophils, erythrocytes (ery), ery mean Corpuscular HGB concentration, ery mean corpuscular HGB, ery distribution width, lymphocytes, hematocrit, monocytes, neutrophils and platelets. The number of participants with a shift from normal at Baseline to abnormal at any time post-Baseline for hematology parameters are summarized. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in Maximum Rate of Urinary Flow (Qmax) at the Indicated Time Points | Baseline, Month 3 and Month 6 | The Qmax is used as an indicator for the diagnosis of enlarged prostate. A lower Qmax may indicate that the enlarged prostate. Qmax was assessed at Baseline (screening), Month 3 and Month 6. Change from Baseline was calculated as Qmax score at specified timepoint minus the Baseline Qmax score. |
| Change From Baseline in the International Prostate Symptom Score (IPSS) at Month 6 | Baseline and Month 6 | The IPSS is a screening tool used to assess the symptoms of prostate related disease. The IPSS questionnaire consists of seven symptoms questions including feeling of incomplete bladder emptying, frequency, intermittency, urgency, weak stream, straining and nocturia, each referring to during the last month, and each involving assignment of a score from 0 to 5 (no symptoms to almost always symptoms) for a total of maximum 35 points. IPSS total is the sum of the scores of seven questions; therefore, the possible total score ranges from 0 to 35 (0-7: Mildly symptomatic; 8-19: Moderately symptomatic; 20-35: Severely symptomatic). IPSS was assessed at Baseline and Month 6. Change from Baseline was calculated as Month 6 IPSS score- minus Baseline IPSS score. |
Countries
Vietnam
Participant flow
Pre-assignment details
Eligible participants with benign prostatic hyperplasia (BPH) entered into a 6-month enrollment period followed by a6-month treatment period and a one-month follow-up period. The total duration of the study was 13 months.
Participants by arm
| Arm | Count |
|---|---|
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg Participants received a combination of 0.5 mg dutasteride and 0.4 mg tamsulosin capsule orally approximately 30 minutes after a meal once daily for 6 months during the treatment period. Participants were followed up to 30 days after the last dose of study medication to evaluate the safety profile of study drug. | 59 |
| Total | 59 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Adverse Event | 3 |
| Overall Study | Lost to Follow-up | 1 |
| Overall Study | Withdrawal by Subject | 3 |
Baseline characteristics
| Characteristic | Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg |
|---|---|
| Age, Continuous | 66.5 Years STANDARD_DEVIATION 8.37 |
| Race/Ethnicity, Customized Asian | 59 Participants |
| Sex: Female, Male Female | 0 Participants |
| Sex: Female, Male Male | 59 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 0 / 59 |
| serious Total, serious adverse events | 1 / 59 |
Outcome results
Primary
Change From Baseline in Total Prostate -Specific Antigen (PSA) at the Indicated Time Points
Serum sample was collected at Baseline, Month 3 and Month 6 for assesment of total PSA. PSA is a substance produced by prostate gland, and the elevated level of PSA indicates prostate cancer or any other non-cancerous condition related to prostate. Change from Baseline in total PSA at Month 3 and Month 6 was calculated as value at specified visist minus Baseline value.
Time frame: Baseline, Month 3 and Month 6
Population: ITT Population. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Change From Baseline in Total Prostate -Specific Antigen (PSA) at the Indicated Time Points | Month 3, n=54 | -1.499 Microgram per liter (ug/L) | Standard Deviation 1.2263 |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Change From Baseline in Total Prostate -Specific Antigen (PSA) at the Indicated Time Points | Month 6, n=52 | -1.824 Microgram per liter (ug/L) | Standard Deviation 1.2413 |
Primary
Free to Total PSA Ratio at the Indicated Time Points
Serum sample was collected at Screening (Baseline for participants with Free to Total PSA ratio at Month 6), and Month 6 for assessment of free to total PSA ratio. PSA is a substance produced by prostate gland, and the elevated level of PSA indicates prostate cancer or any other non-cancerous condition related to prostate. Free to total PSA ratio at Baseline for participants with free to total PSA Ratio at Month 6 and free to total PSA ratio at month 6 are presented.
Time frame: Baseline, Month 6
Population: ITT Population. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Free to Total PSA Ratio at the Indicated Time Points | Baseline, n=50 | 28.207 Ratio | Standard Deviation 10.5868 |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Free to Total PSA Ratio at the Indicated Time Points | Month 6, n=52 | 24.887 Ratio | Standard Deviation 8.1112 |
Primary
Number of Participants With Abnormal Electrocardiogram (ECG) Findings at the Indicated Time Points
A 12 lead ECG was measured at Screening, Month 1 (Visit 1), Month 3 (Visit 3) and Month 6 (Visit 5).
Time frame: Screening, Month 1, Month 3 and Month 6
Population: ITT Population. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number of Participants With Abnormal Electrocardiogram (ECG) Findings at the Indicated Time Points | Month 6, n=52 | 44 Participants |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number of Participants With Abnormal Electrocardiogram (ECG) Findings at the Indicated Time Points | Screening, n=59 | 49 Participants |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number of Participants With Abnormal Electrocardiogram (ECG) Findings at the Indicated Time Points | Month 1, n=56 | 47 Participants |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number of Participants With Abnormal Electrocardiogram (ECG) Findings at the Indicated Time Points | Month 3, n=53 | 50 Participants |
Primary
Number of Participants With Any On-treatment Adverse Events (AEs) or Any Serious Adverse Event (SAEs) and Treatment-related AEs
An AE is defined as any untoward medical occurrence in a participant temporally associated with the use of a medicinal product at any dose, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, is an important medical event that jeopardizes the participants or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition, and is associated with liver injury and impaired liver function.
Time frame: From start of study medication until follow-up (up to 7 months)
Population: Intention-to-Treat (ITT) Population: all enrolled participants regardless of whether or not study treatment was administered.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number of Participants With Any On-treatment Adverse Events (AEs) or Any Serious Adverse Event (SAEs) and Treatment-related AEs | Any AE | 13 Participants |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number of Participants With Any On-treatment Adverse Events (AEs) or Any Serious Adverse Event (SAEs) and Treatment-related AEs | Any SAE | 1 Participants |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number of Participants With Any On-treatment Adverse Events (AEs) or Any Serious Adverse Event (SAEs) and Treatment-related AEs | Any treatment-related AE | 3 Participants |
Primary
Number of Participants With Any Post-treatment Adverse Events (AEs) or Any Serious Adverse Event (SAEs) and Treatment-related AEs
An AE is defined as any untoward medical occurrence in a participant temporally associated with the use of a medicinal product at any dose, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, is an important medical event that jeopardizes the participants or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition, and is associated with liver injury and impaired liver function.
Time frame: From start of study medication until follow-up (up to 7 months)
Population: ITT Population
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number of Participants With Any Post-treatment Adverse Events (AEs) or Any Serious Adverse Event (SAEs) and Treatment-related AEs | Any AE | 2 Participants |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number of Participants With Any Post-treatment Adverse Events (AEs) or Any Serious Adverse Event (SAEs) and Treatment-related AEs | Any SAE | 1 Participants |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number of Participants With Any Post-treatment Adverse Events (AEs) or Any Serious Adverse Event (SAEs) and Treatment-related AEs | Any treatment-related AE | 1 Participants |
Primary
Number of Participants With Clinical Chemistry Values Shift From Normal at Baseline to Abnormal at Any Time Post-Baseline
Blood samples were collected at Screening, Month 1 (Visit 1), Month 3 (Visit 3) and Month 6 (Visit 5) for chemistry laboratory assessments. Clinical chemistry parameters included alanine aminotrasferase (ALT), aspartate aminotrasferase (AST), creatinine, glucose, potassium, protein, sodium and urea. The number of participants with a shift from normal at Baseline to abnormal at any time post-Baseline for a clinical chemistry parameter are summarized.
Time frame: Screening, Month 1, Month 3 and Month 6
Population: ITT Population. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number of Participants With Clinical Chemistry Values Shift From Normal at Baseline to Abnormal at Any Time Post-Baseline | ALT, n=48 | 9 Participants |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number of Participants With Clinical Chemistry Values Shift From Normal at Baseline to Abnormal at Any Time Post-Baseline | AST, n=49 | 6 Participants |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number of Participants With Clinical Chemistry Values Shift From Normal at Baseline to Abnormal at Any Time Post-Baseline | Creatinine, n=51 | 9 Participants |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number of Participants With Clinical Chemistry Values Shift From Normal at Baseline to Abnormal at Any Time Post-Baseline | Glucose, n=47 | 8 Participants |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number of Participants With Clinical Chemistry Values Shift From Normal at Baseline to Abnormal at Any Time Post-Baseline | Potassium, n=52 | 1 Participants |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number of Participants With Clinical Chemistry Values Shift From Normal at Baseline to Abnormal at Any Time Post-Baseline | Protein, n=56 | 4 Participants |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number of Participants With Clinical Chemistry Values Shift From Normal at Baseline to Abnormal at Any Time Post-Baseline | Sodium, n=53 | 0 Participants |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number of Participants With Clinical Chemistry Values Shift From Normal at Baseline to Abnormal at Any Time Post-Baseline | Urea, n=54 | 7 Participants |
Primary
Number of Participants With Hematology Values Shift From Normal at Baseline to Abnormal at Any Time Post-Baseline
Blood samples were collected at Screening, Month 3 (Visit 3) and Month 6 (Visit 5) for hematology laboratory assessments. Hematology parameters included basophils, leukocytes, hemoglobin (HGB), eosinophils, erythrocytes (ery), ery mean Corpuscular HGB concentration, ery mean corpuscular HGB, ery distribution width, lymphocytes, hematocrit, monocytes, neutrophils and platelets. The number of participants with a shift from normal at Baseline to abnormal at any time post-Baseline for hematology parameters are summarized.
Time frame: Screening, Month 3 and Month 6
Population: ITT Population. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number of Participants With Hematology Values Shift From Normal at Baseline to Abnormal at Any Time Post-Baseline | Eosinophils/Leukocytes, n=46 | 5 Participants |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number of Participants With Hematology Values Shift From Normal at Baseline to Abnormal at Any Time Post-Baseline | Ery Mean Corpuscular HGB Concentration, n=44 | 22 Participants |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number of Participants With Hematology Values Shift From Normal at Baseline to Abnormal at Any Time Post-Baseline | Ery Mean Corpuscular Volume, n=42 | 4 Participants |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number of Participants With Hematology Values Shift From Normal at Baseline to Abnormal at Any Time Post-Baseline | Erythrocytes, n=49 | 3 Participants |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number of Participants With Hematology Values Shift From Normal at Baseline to Abnormal at Any Time Post-Baseline | Hematocrit, n=48 | 7 Participants |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number of Participants With Hematology Values Shift From Normal at Baseline to Abnormal at Any Time Post-Baseline | Hemoglobin, n=49 | 2 Participants |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number of Participants With Hematology Values Shift From Normal at Baseline to Abnormal at Any Time Post-Baseline | Leukocytes, n=47 | 7 Participants |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number of Participants With Hematology Values Shift From Normal at Baseline to Abnormal at Any Time Post-Baseline | Lymphocytes/Leukocytes, n=53 | 1 Participants |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number of Participants With Hematology Values Shift From Normal at Baseline to Abnormal at Any Time Post-Baseline | Neutrophils/Leukocytes, n=41 | 5 Participants |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number of Participants With Hematology Values Shift From Normal at Baseline to Abnormal at Any Time Post-Baseline | Platelets, n=53 | 1 Participants |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number of Participants With Hematology Values Shift From Normal at Baseline to Abnormal at Any Time Post-Baseline | Basophils/Leukocytes, n=54 | 0 Participants |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number of Participants With Hematology Values Shift From Normal at Baseline to Abnormal at Any Time Post-Baseline | Ery Mean Corpuscular Hemoglobin, n=36 | 6 Participants |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number of Participants With Hematology Values Shift From Normal at Baseline to Abnormal at Any Time Post-Baseline | Erythrocytes Distribution Width, n=4 | 3 Participants |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number of Participants With Hematology Values Shift From Normal at Baseline to Abnormal at Any Time Post-Baseline | Monocytes/Leukocytes, n=52 | 1 Participants |
Primary
Number Participants With a Negative or Positive Response at the Indicated Time Points
Urine samples were collected at Screening (SC), Month 3 (3M) and Month 6 (6M) for urinalysis laboratory assesment. Final value (FV) is defined as the latest post-Baseline value available in the study for each parameter.Urinalysis parameters included erythrocytes, glucose, ketones, leukocytes and protein. Number of participants with a negative (NEG) or positive (POS) response at the indicated time points are summarized.
Time frame: Screening, Month 3 and Month 6
Population: ITT Population. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number Participants With a Negative or Positive Response at the Indicated Time Points | Erythrocytes, SC, POS, n=59 | 4 Participants |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number Participants With a Negative or Positive Response at the Indicated Time Points | Erythrocytes, SC, NEG, n=59 | 55 Participants |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number Participants With a Negative or Positive Response at the Indicated Time Points | Erythrocytes, FV, POS, n=54 | 7 Participants |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number Participants With a Negative or Positive Response at the Indicated Time Points | Erythrocytes, FV, NEG, n=54 | 47 Participants |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number Participants With a Negative or Positive Response at the Indicated Time Points | Glucose, 3M, NEG, n=54 | 53 Participants |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number Participants With a Negative or Positive Response at the Indicated Time Points | Glucose, 6M, POS, n=52 | 0 Participants |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number Participants With a Negative or Positive Response at the Indicated Time Points | Ketones, SC, POS, n=59 | 0 Participants |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number Participants With a Negative or Positive Response at the Indicated Time Points | Ketones, SC, NEG, n=59 | 59 Participants |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number Participants With a Negative or Positive Response at the Indicated Time Points | Ketones, 3M, POS, n=54 | 2 Participants |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number Participants With a Negative or Positive Response at the Indicated Time Points | Ketones, 6M, POS, n=52 | 1 Participants |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number Participants With a Negative or Positive Response at the Indicated Time Points | Ketones, 6M, NEG, n=52 | 51 Participants |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number Participants With a Negative or Positive Response at the Indicated Time Points | Ketones, FV, POS, n=54 | 1 Participants |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number Participants With a Negative or Positive Response at the Indicated Time Points | Protein, 6M, POS, n=52 | 7 Participants |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number Participants With a Negative or Positive Response at the Indicated Time Points | Protein, 6M, NEG, N=52 | 45 Participants |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number Participants With a Negative or Positive Response at the Indicated Time Points | Protein, FV, POS, n=54 | 8 Participants |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number Participants With a Negative or Positive Response at the Indicated Time Points | Protein, FV, NEG, n=54 | 46 Participants |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number Participants With a Negative or Positive Response at the Indicated Time Points | Erythrocytes, 3M, POS, n=54 | 6 Participants |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number Participants With a Negative or Positive Response at the Indicated Time Points | Erythrocytes, 3M, NEG, n=54 | 48 Participants |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number Participants With a Negative or Positive Response at the Indicated Time Points | Erythrocytes, 6M, POS, n=52 | 6 Participants |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number Participants With a Negative or Positive Response at the Indicated Time Points | Erythrocytes, 6M, NEG, n=52 | 46 Participants |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number Participants With a Negative or Positive Response at the Indicated Time Points | Glucose, SC, POS, n=59 | 3 Participants |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number Participants With a Negative or Positive Response at the Indicated Time Points | Glucose, SC, NEG, n=59 | 56 Participants |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number Participants With a Negative or Positive Response at the Indicated Time Points | Glucose, 3M, POS, n=54 | 1 Participants |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number Participants With a Negative or Positive Response at the Indicated Time Points | Glucose, 6M, NEG, n=52 | 52 Participants |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number Participants With a Negative or Positive Response at the Indicated Time Points | Glucose, FV, POS, n=54 | 0 Participants |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number Participants With a Negative or Positive Response at the Indicated Time Points | Glucose, FV, NEG, n=54 | 54 Participants |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number Participants With a Negative or Positive Response at the Indicated Time Points | Ketones, 3M, NEG, n=54 | 52 Participants |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number Participants With a Negative or Positive Response at the Indicated Time Points | Ketones, FV, NEG, n=54 | 53 Participants |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number Participants With a Negative or Positive Response at the Indicated Time Points | Leukocytes, SC, POS, n=59 | 3 Participants |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number Participants With a Negative or Positive Response at the Indicated Time Points | Leukocytes, SC, NEG, n=59 | 56 Participants |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number Participants With a Negative or Positive Response at the Indicated Time Points | Leukocytes, 3M, POS, n=54 | 0 Participants |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number Participants With a Negative or Positive Response at the Indicated Time Points | Leukocytes, 3M, NEG, n=54 | 54 Participants |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number Participants With a Negative or Positive Response at the Indicated Time Points | Leukocytes, 6M, POS, n=52 | 6 Participants |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number Participants With a Negative or Positive Response at the Indicated Time Points | Leukocytes, 6M, NEG, n=52 | 46 Participants |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number Participants With a Negative or Positive Response at the Indicated Time Points | Leukocytes, FV, POS, n=54 | 6 Participants |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number Participants With a Negative or Positive Response at the Indicated Time Points | Leukocytes, FV, NEG, n=54 | 48 Participants |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number Participants With a Negative or Positive Response at the Indicated Time Points | Protein, SC, POS, n=59 | 9 Participants |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number Participants With a Negative or Positive Response at the Indicated Time Points | Protein, SC, NEG, n=59 | 50 Participants |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number Participants With a Negative or Positive Response at the Indicated Time Points | Protein, 3M, POS, n=54 | 6 Participants |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Number Participants With a Negative or Positive Response at the Indicated Time Points | Protein, 3M, NEG, n=54 | 48 Participants |
Secondary
Change From Baseline in Maximum Rate of Urinary Flow (Qmax) at the Indicated Time Points
The Qmax is used as an indicator for the diagnosis of enlarged prostate. A lower Qmax may indicate that the enlarged prostate. Qmax was assessed at Baseline (screening), Month 3 and Month 6. Change from Baseline was calculated as Qmax score at specified timepoint minus the Baseline Qmax score.
Time frame: Baseline, Month 3 and Month 6
Population: ITT Population. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Change From Baseline in Maximum Rate of Urinary Flow (Qmax) at the Indicated Time Points | Month 3, n=54 | 2.77 Mililiter/seconds | Standard Deviation 4.361 |
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Change From Baseline in Maximum Rate of Urinary Flow (Qmax) at the Indicated Time Points | Month 6, n=52 | 2.01 Mililiter/seconds | Standard Deviation 3.684 |
p-value: <0.001t-test, 2 sided
p-value: <0.001t-test, 2 sided
Secondary
Change From Baseline in the International Prostate Symptom Score (IPSS) at Month 6
The IPSS is a screening tool used to assess the symptoms of prostate related disease. The IPSS questionnaire consists of seven symptoms questions including feeling of incomplete bladder emptying, frequency, intermittency, urgency, weak stream, straining and nocturia, each referring to during the last month, and each involving assignment of a score from 0 to 5 (no symptoms to almost always symptoms) for a total of maximum 35 points. IPSS total is the sum of the scores of seven questions; therefore, the possible total score ranges from 0 to 35 (0-7: Mildly symptomatic; 8-19: Moderately symptomatic; 20-35: Severely symptomatic). IPSS was assessed at Baseline and Month 6. Change from Baseline was calculated as Month 6 IPSS score- minus Baseline IPSS score.
Time frame: Baseline and Month 6
Population: ITT Population. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Change From Baseline in the International Prostate Symptom Score (IPSS) at Month 6 | -8.3 Scores on a scale | Standard Deviation 3.92 |
p-value: <0.001t-test, 2 sided